A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's Lesions
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Lidocaine (Primary)
- Indications Interstitial cystitis
- Focus Therapeutic Use
- Sponsors Allergan
- 11 Sep 2017 Planned End Date changed from 1 May 2018 to 11 Nov 2017.
- 11 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Dec 2016 Planned End Date changed from 1 Jun 2017 to 1 May 2018.